Red Yeast Rice for Health & Longevity - Quick Reference Sheet

Red Yeast Rice for Health & Longevity

Created on 10/09/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Red yeast rice is fermented rice sold as a dietary supplement, used mainly for cholesterol management. Its main active compound is chemically identical to a prescription cholesterol-lowering drug, so effects and risks follow that drug's pattern. Blood cholesterol lowering has the strongest evidence, though one short trial found no change. Muscle, liver, and kidney injury are the main harms. Product content varies; fungal toxin has been found in many products. (Full Review)

Protocol

Dose
1,200 to 2,400 mg/day
Red yeast rice in two divided doses, one before bedtime; content per capsule varies
Monacolin K
About 3 mg/day
Described as well tolerated; severe cases occurred at this intake
Time of day
Evening
Evening lovastatin dosing was more effective than morning; inferred for red yeast rice
Time to effect
LDL cholesterol
12 weeks
Dropped 43 mg/dL at week 12; lovastatin's maximal response occurs within 4 to 6 weeks
Total cholesterol
8 weeks
Fell significantly by week 8
Cardiovascular events
Years
Event outcomes took years; the longest outcome trial ran about 4.5 years

Benefits

Contraindications
  • Pregnant or lactating individuals (theoretical)
  • Active liver disease or unexplained persistent transaminase (liver enzyme) elevation (theoretical)
  • Strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, nelfinavir, nefazodone; theoretical)
  • Prior rhabdomyolysis or liver injury attributed to a statin or red yeast rice (theoretical)
  • Hypersensitivity to any component of the product (theoretical)
  • Gemfibrozil
  • Cyclosporine (theoretical)
  • Protease inhibitors (e.g., ritonavir; theoretical)
  • Other monacolin K or lovastatin products (theoretical)
Key Interactions
  • Other cholesterol drugs (atorvastatin, simvastatin, rosuvastatin, fenofibrate; theoretical)
  • Diltiazem, verapamil, dronedarone, danazol, amiodarone, colchicine, ranolazine (theoretical)
  • Warfarin (theoretical)
  • Niacin at 1 g/day or more (theoretical)
  • Cimetidine (theoretical)
  • St. John's wort (theoretical)
  • Soluble fiber, berberine, bergamot, artichoke, plant sterols and stanols (additive cholesterol-lowering effects)
  • Grapefruit juice (theoretical)
  • Substantial alcohol intake (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Muscle symptoms and muscle injury; liver injury and enzyme elevation; kidney injury linked to specific products; gastrointestinal and skin reactions; incident diabetes
  • Speculative: Fetal harm in pregnancy

Monitoring

Marker Target Why
LDL cholesterol Below 100 mg/dL (coronary disease or equivalent); below 130 (two or more risk factors); below 160 (zero or one risk factor) Marker expected to change
ALT and AST ALT about 7–56 U/L, AST about 10–40 U/L (standard reference range) Safety check; unexplained persistent elevation contraindicates lovastatin
Creatine kinase (CK) About 30–200 U/L (standard reference range) Safety check; myopathy is defined as above 10 times the upper limit of normal
eGFR and electrolytes No established target; track change from own baseline Safety check; the Japanese cases defined low eGFR as below 60 mL/min/1.73 m²
HbA1c and fasting glucose No established target; track change from own baseline Safety check; the label reports statin-class increases

Cadence: Baseline before starting; lipid panel, liver enzymes, and kidney function with electrolytes repeated at about 8 to 12 weeks, then every 6 to 12 months; creatine kinase checked promptly if muscle symptoms occur; glucose markers rechecked at the 6- to 12-month visits

Qualitative Assessment

  • Muscle pain, tenderness, or weakness, and dark urine
  • Digestive upset, skin reactions, and fatigue
  • Sleep quality, particularly with evening dosing